Literature DB >> 22503309

The Canadian Transfusion Surveillance System: what is it and how can the data be used?

Julie Ditomasso1, Yang Liu, Nancy M Heddle.   

Abstract

Hemovigilance systems are important programs for: monitoring trends of known risks; evaluating effectiveness of steps taken to reduce risks; providing data to support recommendations for change and guideline development; and contributing overall to the safety of transfusion. The Transfusion Transmitted Injury Surveillance System is the hemovigilance system implemented in Canada. It evolved in 1999 as a pilot program and expanded across Canada in 2005. Each province reports their adverse reactions to the transfusion of blood products and plasma proteins to the Public Health Agency of Canada (PHAC) at predetermined intervals. PHAC reconciles, summarizes the data and publishes a report approximately 2 years after the data are collected. This is considered a passive reporting system but in spite of the delays, the program provides useful information to address a variety of questions. Examples include: assessing the impact of a provincial patient transfusion history registry in Québec on reporting of hemolytic transfusion reactions; identifying trends of bacterial contamination of blood products and assessing the impact of interventions on these events; and the impact of male-only plasma on the incidence of Transfusion Related Acute Lung Injury. Although hemovigilance data has been successfully used to improve blood safety, we must continue to explore ways to utilize such data to improve and implement safe transfusion practices.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22503309     DOI: 10.1016/j.transci.2012.03.024

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  5 in total

1.  Evaluation of the National Healthcare Safety Network Hemovigilance Module for transfusion-related adverse reactions in the United States.

Authors:  Chris Edens; Kathryn A Haass; Melissa Cumming; Anthony Osinski; Lynne O'Hearn; Kelly Passanisi; Lynn Eaton; Paul Visintainer; Alexandra Savinkina; Matthew J Kuehnert; Sridhar V Basavaraju; Chester Andrzejewski
Journal:  Transfusion       Date:  2018-11-14       Impact factor: 3.157

Review 2.  Would a National Antibody Register contribute to improving patient outcomes?

Authors:  Zachary Powell; Nan Jiang; Rajeshwori Shrestha; Denise E Jackson
Journal:  Blood Transfus       Date:  2021-03-12       Impact factor: 3.443

3.  Performance Assessment of Internal Quality Control (IQC) Products in Blood Transfusion Compatibility Testing in China.

Authors:  Gui-Ping Xu; Li-Fang Wu; Jing-Jing Li; Qi Gao; Zhi-Dong Liu; Qiong-Hua Kang; Yi-Jun Hou; Luo-Chuan Zhang; Xiao-Mei Hu; Jie Li; Juan Zhang
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

Review 4.  When to transfuse your acute care patient? A narrative review of the risk of anemia and red blood cell transfusion based on clinical trial outcomes.

Authors:  Gregory M T Hare; Melina P Cazorla-Bak; S F Michelle Ku; Kyle Chin; Nikhil Mistry; Michael C Sklar; Katerina Pavenski; Ahmad Alli; Adriaan Van Rensburg; Jan O Friedrich; Andrew J Baker; C David Mazer
Journal:  Can J Anaesth       Date:  2020-08-07       Impact factor: 6.713

Review 5.  Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety.

Authors:  Paula H B Bolton-Maggs; Hannah Cohen
Journal:  Br J Haematol       Date:  2013-09-14       Impact factor: 6.998

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.